A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer ...
Apr 26, 2009
5 / 5 (6)
0
(Phys.org)—One of the main reasons that nanoparticles can boost the effectiveness of an anticancer drug while decreasing its toxicity is that they are able to accumulate at cancerous sites in the body through the abnormally ...
Feb 22, 2013
not rated yet
0
An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small ...
Nov 30, 2010
5 / 5 (2)
0
According to a study presented at SNM's 57th Annual Meeting, molecular imaging can evaluate and optimize non-Hodgkin's lymphoma therapy with Zevalin, a front-line radioimmunotherapy drug that uses a dose of radioactive material ...
Jun 07, 2010
not rated yet
0
Bladder cancer often becomes aggressive and spreads in patients despite treatment, but now researchers at the Kimmel Cancer Center at Jefferson have identified a protein they believe is involved in pushing tumors to become ...
May 14, 2010
not rated yet
0
Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a jour ...
Jun 15, 2010
4 / 5 (1)
0
Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators ...
Jun 01, 2010
not rated yet
0
Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," ...
Apr 19, 2010
not rated yet
0
Scientists at The University of Texas M. D. Anderson Cancer Center have discovered genetic variations in the inflammation pathway that reduce the likelihood of recurrence and increase survival of patients with non-muscle ...
Apr 20, 2009
not rated yet
0
